Chapter 8 - WHEN PIPER TOOK THE MICROPHONE
The hearing room in Phoenix smelled of old carpet, fresh coffee, and anxiety.
Piper sat at the front with her black notebook resting across her knees. She had dressed herself in the same green blouse she'd worn to a college interview the previous spring. It felt important to arrive as a person with a life beyond the controversy.
Across the aisle sat Malcolm Sloane and Adrian Kessler, flanked by attorneys. They did not look at her.
Genevieve took a seat behind Piper rather than beside her. It was a small decision, but it told everyone watching that her daughter would speak for herself.
The hearing was part of a broader state review involving patient complaints, with federal device regulators and independent experts receiving the relevant records. Its purpose was to gather evidence and recommend protective measures; it was not a criminal trial. Piper had been told that repeatedly. She appreciated the distinction. She was tired of people promising punishment before they had proved the facts.
A panel chair introduced the first witness, Dr. Saira Patel. The physician described Piper's injury, the purpose of her orthoses, the way support could improve some functions while still creating risks, and the limits of what doctors knew about the specific joint mechanism.
“Does Ms. Larkin's pain prove the product is defective?” an attorney asked.
“No,” Dr. Patel answered. “It proves she is experiencing pain. That fact requires serious assessment. We can investigate mechanical contribution without pretending every symptom has one cause.”
“Then you cannot say the device caused her suffering.”
“I can say the documented joint movement occurred during an episode of pain, and that the clinical team stopped using the affected device pending evaluation. That is a safety decision, not a verdict.”
The chair thanked her.
Elise Navarro followed. She played the gait-lab video and explained precisely what the clinicians had observed. Independent engineers described the preliminary mechanical investigation, carefully distinguishing observed movement from hypotheses about underlying design.
The room grew quieter when Nina Ortega testified.
She explained that earlier bench testing had identified unusual reset behavior under certain off-center loads. Her objection to reducing the scope of subsequent tests had been recorded, then reframed as a scheduling concern.
“Were you certain the joint would injure patients?” a lawyer asked.
“No. We didn't have sufficient data to draw that conclusion. That's why I wanted further testing.”
“Did you tell management?”
“Yes.”
“What did management do?”
“They told us to meet the revised acceptance criteria.”
“Did the dashboard become more accurate?”
“The dashboard became less likely to flag those events. Whether that was clinically appropriate required validation that I did not see completed.”
Her answer was a devastating thing precisely because she didn't exaggerate.
When Genevieve's turn came, a hush settled over the room. The billionaire took the oath and placed both hands on the table. She looked at Piper before answering the first question.
“Yes,” she said, “I approved a financing package that supported the Series R launch.”
“Did you review the underlying patient complaints?”
“No.”
“Why not?”
“I relied on a risk summary prepared by advisers. I believed the statement that there were no unresolved material safety concerns.”
“Do you now consider that reliance reasonable?”
“No. I had the resources and the influence to ask for the underlying records, especially because my own daughter used the equipment. I did not.”
One attorney leaned forward. “Are you suggesting you were deceived?”
“Some information was summarized in a way that concealed its importance. Investigators will determine the legal responsibility for that. But I am not asking this panel to excuse my failure to read what I signed.”
Piper closed her eyes.
All her life, she'd heard her mother explain what she had done to protect her. This was the first time she'd heard her explain what she had failed to do.
Next came Adrian Kessler.
He entered with the stiff dignity of someone accustomed to standing beneath applause. The questions stripped it away slowly. His initials appeared on the memorandum warning that acknowledging the reset issue could jeopardize the release schedule. Original test protocols showed a broader range of loads than the final release summary. He confirmed that engineering staff had raised concerns and that he accepted a narrower test plan.
“I believed the changes could be addressed through monitoring,” he said.
“Monitoring that filtered certain movement out of the record?” the chair asked.
“We believed those events were sensor artifacts.”
“What evidence established they were artifacts?”
He searched his notes. “The product team made a judgment.”
“Was that judgment supported by a completed clinical validation of the revised filter?”
He looked at his attorney.
“I cannot identify one today.”
The answer landed without a sound.
Malcolm Sloane testified that the company had acted in good faith and had not knowingly sold a dangerous product. He defended the cost-saving redesign as a standard manufacturing decision and disputed the suggestion that savings drove safety choices. The chair pressed him on the difference between internal complaint totals and summaries given to patients and investors. He said categories had been consolidated by professionals and that the underlying data was available to authorized reviewers.
“Then why was a patient told she was the only one reporting a double click?”
“I cannot speak to a particular customer-service exchange.”
Piper stared at him. She had spent eighteen months being told her experience was too specific to matter. Now the man responsible for the company was saying it was too specific to answer.
When her name was called, she wheeled herself forward without assistance.
“Ms. Larkin,” the panel chair said gently, “you may take your time.”
“I've been taking my time for eleven years,” she answered, earning a few surprised smiles. “I'll try not to take too much of yours.”
She opened the notebook.
“I was eight when I was injured in a car crash. Since then, people have talked about my body with an urgency that sometimes makes them forget I live in it. My mother spent money because she loved me. My doctors worked hard because they cared. Engineers wanted to make something better. All of those things are true.”
She turned a page.
“It's also true that I told people a joint was catching. I was told the equipment was fine. I was told another opinion would create confusion. I was told the pain could be stress. Maybe some of my pain was stress. But I wasn't imagining the sound.”
The chair asked what she wanted the review to accomplish.
“I want people who use equipment to be treated as witnesses to their own experience. Not as proof that a company is wonderful. Not as evidence that a company is terrible. People. I want complaints taken seriously even when software says green. And I want patients to know if other people have described the same problem.”
She looked toward the audience.
“I also want it understood that a failed device doesn't mean a failed person. I'm tired of hearing the phrase 'she never gave up' when what it means is that I kept using something that hurt because I thought stopping would disappoint everybody.”
Boone felt his throat tighten. He remembered Mabel apologizing every time her brace came off for the night, as though comfort were a sign of surrender.
Piper continued. “I'm grateful for every tool that helps me live. But I should never have to be grateful enough to stop asking whether it's safe.”
She closed the notebook.
The room stayed silent for three seconds before the chair thanked her. The pause was not neglect. People were listening.
The hearing lasted into the afternoon. The panel recommended accelerated independent review of the affected revision, strengthened patient notification, and preservation of all complaint and engineering records. Regulators announced interim risk communications and coordinated evaluations, with further corrective actions to follow from the evidence. Nobody declared every Series R unit unsafe on the spot. Nobody claimed a prototype in Tucson had solved the problem. The restraint disappointed the reporters who wanted a dramatic headline and reassured the clinicians responsible for real patients.
Outside, cameras crowded the steps. Genevieve shielded her eyes from the sun as reporters shouted about her fortune, the lawsuit she faced, and whether she intended to resign from the company board.
She answered one question.
“I am providing the records I should have requested years ago. My daughter has earned the right to be heard. The rest will proceed through independent review.”
Then she stepped away.
Boone found Piper at a quiet side entrance watching traffic.
“You were something up there,” he told her.
“I was shaking.”
“Most people do when they're brave.”
“I don't want to be brave every day.”
“You shouldn't have to be.”
She smiled. “You sound like my grandmother.”
“She's probably smarter than me.”
“She is. She texted me a picture of a cactus wearing sunglasses.”
For a moment they laughed like ordinary friends after an exhausting afternoon.
Nora arrived carrying an update. The university had received notice that the demand to destroy Boone's prototype would not be enforced while questions about intellectual property were assessed. Separately, regulators had invited the research team to present its bench model as an exploratory design concept, not a clinical alternative.
“That's good news,” Boone said.
“It's a beginning,” Nora replied.
From behind them came a voice Boone recognized.
“Mr. Holloway.”
Adrian Kessler stood a few feet away, alone. Without the stage lights he looked older. His face had the gray fatigue of someone who had begun to count the people hurt by his decisions.
“I owe you an apology,” he said.
Boone glanced at Piper. “You don't owe me the first one.”
Kessler turned toward her.
She held his gaze.
“Three years ago,” she said, “you told me we'd talk afterward.”
“I remember.”
“No. You remember now. That's different.”
Kessler nodded slowly. “You're right.”
“Then tell the investigators everything. I don't need you to feel terrible in front of me. I need you to stop protecting the story you told about the machine.”
He looked as if he wanted to defend himself. Instead he said, “I will provide the full technical record.”
He left without asking for forgiveness.
Piper watched him go.
“I always thought the moment somebody admitted I was right, I'd feel better,” she said.
“Do you?” Boone asked.
“A little.”
She looked toward the mountains beyond the city.
“But what I really feel is ready to do something else with my life.”
Genevieve appeared at the top of the steps carrying Piper's jacket. For once, she didn't drape it over her daughter's shoulders automatically. She held it out and waited.
May you like
Piper took it herself.
It was a small gesture. And for the two of them, it felt like the beginning of something larger than winning a hearing.
